Lifecore Biomedical (NASDAQ:LFCR) Issues Earnings Results

Lifecore Biomedical (NASDAQ:LFCR) posted its quarterly earnings data on Monday. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05), Zacks reports. The company had revenue of $35.75 million for the quarter, compared to analyst estimates of $35.31 million. Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 25.59%.

Here are the key takeaways from Lifecore Biomedical’s conference call:

• The company reported strong recent results with Q4 2025 revenues of $35.7 million (+10%) and a seven‑month transition period revenue of $75.5 million (+20%)
• Lifecore highlighted major operational wins supporting a 2027 inflection—successful qualification of its five‑head isolator filler for Europe/Asia and HA qualification for Japan position it to support a planned >2x increase in aseptic fill demand from its largest customer.
• The company pushed expected launch timelines for its late‑stage pipeline from 2026–2029 to 2027–2030, citing customer development changes and financing issues, which delays potential commercialization revenue.
• Management has materially reduced operating expenses, improved liquidity to approximately $39 million (including ~$17.5M cash), paid down ~$20M of debt, and expects >$10M free cash flow in 2026, supporting financial stability.
• 2026 guidance: revenue of $120–125 million, net loss of $28.9–33.4 million, and adjusted EBITDA of $20.5–25 million, with the outlook explicitly contingent on customer supply‑chain shifts, inventory timing and a delayed commercial launch.

Lifecore Biomedical Stock Performance

NASDAQ:LFCR opened at $4.36 on Tuesday. The company has a market cap of $163.37 million, a P/E ratio of -4.07 and a beta of 0.62. Lifecore Biomedical has a twelve month low of $4.20 and a twelve month high of $8.98. The company’s 50-day moving average price is $7.54 and its 200-day moving average price is $7.49. The company has a current ratio of 2.80, a quick ratio of 1.67 and a debt-to-equity ratio of 113.76.

More Lifecore Biomedical News

Here are the key news stories impacting Lifecore Biomedical this week:

• Positive Sentiment: Barrington Research upgraded LFCR from “market perform” to “outperform” with a $5.50 price target (about ~26% above the current price), providing an analyst-driven catalyst and a potential upside reference for investors. Barrington Upgrade
• Positive Sentiment: Company reported recorded fourth-quarter revenues of $35.7M (slightly above estimates), announced five new programs in the 2025 transition period including two commercial site transfers, and highlighted organizational initiatives to improve margins—signals of top-line momentum and commercial traction. Press Release Earnings Highlights
• Neutral Sentiment: Management is targeting a 12% revenue CAGR through 2029 but said several midterm pipeline milestones have shifted—this implies multi-year growth assumptions remain intact but timing uncertainty for pipeline-related revenue. Seeking Alpha Article
• Negative Sentiment: EPS missed expectations—reported a ($0.16) loss vs. consensus ($0.11) loss—while the company shows a negative net margin (~25.6%) and an extreme negative return on equity, which raises near-term profitability concerns and likely pressured the share price. Earnings Transcript
• Negative Sentiment: Law firm Johnson Fistel announced an investigation into potential investor claims involving Lifecore executives—legal scrutiny can amplify downside risk, increase uncertainty and weigh on sentiment. GlobeNewswire Investigation Notice

Institutional Trading of Lifecore Biomedical

A number of hedge funds have recently bought and sold shares of the business. Quarry LP purchased a new position in Lifecore Biomedical in the 3rd quarter worth approximately $28,000. BNP Paribas Financial Markets boosted its holdings in shares of Lifecore Biomedical by 92.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company’s stock worth $43,000 after purchasing an additional 2,786 shares during the last quarter. State of Wyoming purchased a new stake in shares of Lifecore Biomedical in the second quarter valued at approximately $69,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Lifecore Biomedical in the second quarter valued at approximately $88,000. Finally, Graham Capital Management L.P. acquired a new stake in shares of Lifecore Biomedical in the fourth quarter valued at approximately $111,000. Institutional investors and hedge funds own 83.36% of the company’s stock.

Analyst Upgrades and Downgrades

LFCR has been the subject of a number of research reports. Barrington Research raised shares of Lifecore Biomedical from a “market perform” rating to an “outperform” rating and set a $5.50 target price for the company in a research note on Tuesday. Weiss Ratings reiterated a “sell (d)” rating on shares of Lifecore Biomedical in a report on Thursday, January 22nd. Finally, Zacks Research upgraded Lifecore Biomedical to a “hold” rating in a research note on Thursday, January 1st. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $5.50.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.

Recommended Stories

• Five stocks we like better than Lifecore Biomedical
• The gold chart Wall Street is terrified of…
• Elon Musk already made me a “wealthy man”
• Silver paying 20% dividend. Plus 68% share gains
• Unlocked: Elon Musk’s Next Big IPO
• 1,500 Banks Just Handed the Fed Your Bank Account